Avidity Biosciences

Nasdaq:  RNA

Filing Date:  05/22/20

Launch Date:  06/08/20

Price Range:  $14.00 - $16.00

Shares Offered (Pre-Shoe, mm):  10.0

Primary Shares (mm):  10.0

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $150.0

% Secondary:  0.0%

Shares Outstanding (mm):  31.0

Market Value at IPO Midpoint (mm):  $464.3

Offering as % of Market Value:  32.3%

Bookrunners:  Cowen | SVB Leerink | Credit Suisse | Wells Fargo

Major Holders:  RTW Investments | Cormorant | Eli Lilly & Co. | ALETHEA Capital Management | EcoR1 Capital

Description:  Avidity is pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.

Note:  Emerging Growth Company

Reference Link:  S-1/A